Interna Therapeutics has announced a research collaboration with Daiichi Sankyo, through its Daiichi Sankyo Research Institute Boston, to evaluate the use of Interna’s MNM technology as a delivery enhancer for targeted therapeutic modalities.

Under the terms of the agreement, the collaboration will focus on integrating MNM molecules with targeting approaches to improve intracellular delivery, functional activity, and overall therapeutic performance across selected programs. The agreement provides a framework for potential expansion into broader research and additional programs based on successful outcomes.

This collaboration reflects growing interest in Interna’s MNM platform from leading global pharmaceutical companies and further expands the company’s portfolio of strategic partnerships.

Interna’s MNM platform is designed to enable efficient intracellular delivery of diverse therapeutic cargos, including nucleic acids and other macromolecules, without reliance on traditional delivery systems. By enhancing intracellular access and tissue penetration, MNM has the potential to significantly improve the efficacy of targeted therapies across multiple indications.

Yuval Gottenstein, CEO, Interna Therapeutics, said, “We are very pleased to collaborate with Daiichi Sankyo, a global leader in the discovery of innovative therapeutics. This collaboration reflects growing recognition of the MNM platform as a powerful approach to overcoming one of the most fundamental challenges in drug development, efficient intracellular delivery. We believe that combining our MNM technology with advanced targeting strategies has the potential to unlock new levels of precision and efficacy across a wide range of therapeutic modalities, and we look forward to advancing this work together.”

The collaboration will initially focus on preclinical evaluation, with the potential to expand into broader research activities and additional programs. Financial terms of the collaboration were not disclosed.